Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03219476 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
A Phase 2 study, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT03219476 is a Phase 2 study that has completed, run by Medical College of Wisconsin. The registered enrollment target is 37 participants.
The verdict
NCT03219476, a Phase 2 study, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
This is an exploratory interventional study that initiates standard-of-care anti-estrogen treatment preoperatively for four weeks.
Interventions
- DRUG Tamoxifen
- DRUG Anastrozole
- DRUG Letrozole
- DRUG Exemestane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2017-02-05 |
| Est. Completion | 2025-03-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03219476
The ClinicalTrials.gov registry entry for NCT03219476 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Tamoxifen is the first listed.
NCT03219476 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03219476 about?
NCT03219476 is a clinical study titled "Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer". This is an exploratory interventional study that initiates standard-of-care anti-estrogen treatment preoperatively for four weeks.
What is the current status of trial NCT03219476?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2017-02-05. Estimated completion is 2025-03-20.
What interventions are being tested in trial NCT03219476?
The interventions under investigation include: Tamoxifen (DRUG), Anastrozole (DRUG), Letrozole (DRUG), Exemestane (DRUG).
Who is sponsoring clinical trial NCT03219476?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.